Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Vertical Aerospace FY2025 Earnings Call - Full Transition Imminent, but Cash Runway Forces Capital Strategy
Vertical says Valo is finally in the home stretch. Piloted transition is in the tail end of testing, conducted under direct U.K. CAA oversight, and the company expects closure of the remaining flight ...
- Piloted transition is in the final innings, described as the tail of the S-curve, with less than 10% of transition test points remaining and management expecting completion imminently once weather and final data checks align.
- Flight testing is being conducted under disciplined U.K. CAA oversight using the companys DOA procedures, effectively running a prototype certification dry run to reduce downstream certification risk.
- Weather was a material drag on testing in early 2026, including a run of roughly 46 rain days that delayed flight opportunities and extended the timeline.
- +13 more takeaways
Cadeler Q3 2025 Earnings Call - EUR 2.8bn backlog, 2027 fully booked as company pivots to full-scope foundation T&I
Cadeler closed 2025 ahead of guidance, reporting a beefy EUR 2.8 billion backlog, strong utilization and a EUR 425 million EBITDA for the year. Management is shifting the company from a charter/day-ra...
- Backlog at EUR 2.8 billion at year-end 2025, providing multi-year earnings visibility; management says 80% of the backlog has reached final investment decision.
- 2025 financials ahead of guidance: reported revenue around EUR 620 million, EBITDA EUR 425 million and net profit EUR 280 million.
- Operational execution: Four new builds delivered on time and on budget in 2025; fleet average age now five years and Cadeler claims the largest, most versatile fleet in the market.
- +14 more takeaways
Heidmar Maritime Q4 2025 Earnings Call - Red Sea disruption turbocharges tanker rates, Q1 set to be a record
Heidmar reported sharp revenue growth in 2025 driven by a larger managed fleet, short-term charters and the April 2025 start of PSV ACE, yet posted a full-year loss after a string of non-cash charges ...
- Q4 revenue rose to $25.1 million, up from $5.3 million in Q4 2024, driven by managed fleet growth, more short-term voyage and time charters, and PSV ACE starting operations in April 2025.
- Full-year 2025 revenue jumped to $55.9 million from $29.0 million in 2024, reflecting fleet expansion and stronger freight markets.
- Continuing operations net loss for 2025 was $8.6 million, versus net income of $1.9 million in 2024, pulled down by $5.0 million of stock-based compensation amortization and $3.9 million of unrealized earn-out fair value expense.
- +12 more takeaways
Lument Finance Trust Fourth Quarter 2025 Earnings Call - CLO Boosts Liquidity but Reserves and REO Keep Dividend Under Pressure
Lument closed Q4 2025 with a stopgap of liquidity and fresh paper after executing the LMNT 2025-FL3 CLO, but headline performance was mixed. GAAP net loss was $0.17 per share, distributable earnings w...
- Q4 GAAP net loss was $0.17 per common share; distributable earnings were approximately $0.00 for the quarter.
- Board declared and maintained a quarterly dividend of $0.04 (Q4 2025 and Q1 2026); cumulative dividends for 2025 totaled $0.22 per share.
- LMNT 2025-FL3 CLO closed in December: $664 million transaction, effective advance rate ~88%, weighted average cost of funds ~SOFR + 191 bps, 30-month reinvestment period through June 2028.
- +12 more takeaways
Hesai Group Q4 2025 Earnings Call - GAAP Profitability and a 3-3.5M 2026 Shipment Leap
Hesai closed 2025 as the first lidar vendor to report a full-year GAAP profit, delivering CNY 436 million in net income on CNY 3+ billion of revenue and a 1.6 million unit shipment run rate. Managemen...
- Hesai reported industry-first full-year GAAP net income of CNY 436 million for 2025, with full-year revenue just over CNY 3 billion, up 46% year-over-year.
- Shipments accelerated to about 1.6 million units in 2025, including nearly 240,000 robotics lidars; management raised 2026 shipment guidance to 3.0–3.5 million units.
- Gross margin remained above 40% in 2025, operating expenses (ex-other operating income) fell by CNY 88 million despite strong revenue growth, and operating cash flow was positive CNY 117 million.
- +12 more takeaways
Concentrix First Quarter 2026 Earnings Call - AI bookings surge while margins remain pressured
Concentrix delivered a steady top line and clear evidence that its AI push is moving from promise to commercial traction, but the transition is compressing near-term margins. Revenue was roughly $2.5 ...
- Revenue was approximately $2.5 billion in Q1 2026, up 1.9% on a constant currency basis and over 5% on a reported basis.
- Signed annual contract value for solutions including AI more than doubled quarter over quarter, signaling a sharp shift in go-to-market mix toward higher-value tech offerings.
- Wins with technology were up more than 61% year over year in Q1, and Concentrix closed close to 60 enterprise iX suite deals in the quarter, including its largest iX Hero contracts to date with two Fortune 50 clients.
- +15 more takeaways
Sanara MedTech Q4 2025 Earnings Call - Surpassed $100M Revenue, Reaffirmed 2026 Guidance Backed by Vizient Win
Sanara MedTech closed 2025 with clear momentum, crossing $100.0 million of net revenue for the first time, expanding gross margins to about 93%, and producing positive operating cash flow despite the ...
- Sanara MedTech generated $103.1 million of net revenue in full year 2025, up 19% year over year, the first time the company exceeded $100 million.
- Fourth quarter 2025 net revenue was $27.5 million, up 5% year over year, or up 13% ex the $1.8 million of Hurricane Helene driven BIASURGE sales in Q4 2024.
- Gross margin expanded roughly 200 basis points to approximately 93% for full year 2025, with Q4 gross margin ~93%, driven by soft tissue product mix and lower CellerateRX Surgical manufacturing costs.
- +12 more takeaways
NRx Pharmaceuticals Q4 2025 Earnings Call - KETAFREE bioequivalence clears path to commercialization; one hit could drive profitability
NRx reported concrete progress across three near-term commercial and regulatory paths, with a preliminary FDA determination of bioequivalence for its preservative-free ketamine candidate, KETAFREE, po...
- FDA issued a preliminary determination of bioequivalence for KETAFREE versus Ketalar, a major hurdle cleared for the ANDA pathway.
- NRx manufactured three registration batches of KETAFREE, with plans for about 200,000 blow-fill-seal units to be warehoused at approval.
- Company filed a suitability petition in August 2025 and an ANDA in September 2025; FDA stability review and pre-approval plant inspection remain as standard final steps.
- +12 more takeaways
Cheetah Mobile Q4 2025 Earnings Call - Non-GAAP Profitability Achieved as AI and Robotics Take Half the Revenue
Cheetah Mobile says 2025 was a reset year, with internet cash flow stabilizing the business while AI and robotics moved from lab curiosity to meaningful revenue. Management touts full year non-GAAP op...
- Management says 2025 marked a stabilization, with total revenue up materially year over year, management citing growth in the mid-to-high 40% range and total revenue of roughly RMB 1,150 million for the year.
- Company reported full year non-GAAP operating profit of RMB 14 million, its first non-GAAP operating profitability in six years, while GAAP operating loss narrowed to RMB 179 million from RMB 437 million in 2024.
- AI and other businesses became a dominant mix shift, accounting for roughly half of total revenue in the fourth quarter and about 46.5% for the full year, per management statements.
- +13 more takeaways
LightInTheBox Q4 2025 Earnings Call - Record Q4 Profit as Branded Apparel and AI Drive Margin Expansion
LightInTheBox reported a clear turnaround in 2025, posting consecutive profitable quarters and a record Q4 net income as the company shifts from a pure e-commerce model to a consumer lifestyle and bra...
- Q4 2025 revenue: $63.0 million, up 9% year-over-year, marking renewed top-line growth in the quarter.
- Q4 2025 gross profit: $39.0 million, up 16% year-over-year; Q4 gross margin rose to 63% from 59% a year earlier.
- Q4 2025 net income: $3.3 million, versus $0.5 million in Q4 2024, the company’s highest quarterly profit since 2022.
- +12 more takeaways